Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biopharmaceutical company that focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Additionally, the company’s preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors.

Celyad Oncology SA has a number of strategic partnerships and collaborations in place to support its research and development efforts. It has a licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform.

The company has also established a number of collaborations with leading academic institutions and research organizations to further its research and development efforts. Celyad Oncology SA has a collaboration with the University of Leuven, Belgium, to develop and evaluate CAR-T therapies in preclinical models. It also has a collaboration with the University of Maastricht, Netherlands, to develop CAR-T therapies for the treatment of solid tumors. Additionally, the company has collaborations with the University of Oxford, UK, and the University of Michigan, USA, to evaluate the safety and efficacy of its CAR-T therapies in clinical trials.

Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. The company is listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD.